REG - Kromek Group PLC - First US DHS Contract for Biosecurity for $5.9m

KromekAnnouncement

26/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231026:nRSZ3787Ra&default-theme=true

RNS Number : 3787R  Kromek Group PLC  26 October 2023

26 October 2023

 

Kromek Group plc

("Kromek" or the "Group")

 

First US Department of Homeland Security Contract for Biosecurity

Award of $5.9m contract from US Government

 

Kromek Group plc (AIM: KMK), a leading developer of radiation and
bio-detection technology solutions for the advanced imaging and CBRN detection
segments, is pleased to announce that it has been awarded a $5.9m contract
from the US Department of Homeland Security ("DHS") Countering Weapons of Mass
Destruction ("CWMD") Office for the research and development of technologies
focusing on an agent agnostic bio-detection system. The contract has been
awarded under a four-year programme, which commences immediately, and the
Group expects to receive $874k during the first year base period.

 

Arnab Basu, CEO of Kromek Group, said: "We are pleased to have been awarded
this new contract for the research and development of agent agnostic
biosecurity technologies, which will build on our existing expertise and
technology in the field of automated bio-detection solutions. It is our first
biosecurity contract from the Department of Homeland Security and underscores
our belief that there are significant market opportunities in this area, as
our technologies align well with government biosecurity strategies.

 

"This programme directly addresses a CWMD Office priority focused on the
detection, classification and identification of bioterrorism attacks.
Biological threats are an increasing priority for governments, particularly in
light of the pandemic. The output of the programme is aimed at providing
increased capability to detect and identify biological threats in response to
the operational needs of the  Department of Homeland Security and will be an
important step in making the world safer from the threat of bioterrorism and
other biological threats."

 

 

For further information, please contact:

 

 Kromek Group plc
 Arnab Basu, CEO                                                        +44 (0)1740 626 060

 Paul Farquhar, CFO

 Cavendish Capital Markets Limited (Nominated Adviser and Broker)        
 Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance            +44 (0)20 7220 0500

 Tim Redfern/Charlotte Sutcliffe - ECM

 Michael Johnson/Tamar Cranford-Smith - Sales

 Gracechurch Group (Financial PR)
 Harry Chathli/Claire Norbury/Henry Gamble                              +44 (0)20 4582 3500

 

 

Kromek Group plc

 

Kromek Group plc is a leading developer of radiation detection and
bio-detection technology solutions for the advanced imaging and CBRN detection
segments. Headquartered in County Durham, UK, Kromek has manufacturing
operations in the UK and US, delivering on the vision of enhancing the quality
of life through innovative detection technology solutions.

 

The advanced imaging segment comprises the medical (including CT and SPECT),
security and industrial markets. Kromek provides its OEM customers with
detector components, based on its core cadmium zinc telluride (CZT) platform,
to enable better detection of diseases such as cancer and Alzheimer's,
contamination in industrial manufacture and explosives in aviation
settings.

 

In CBRN detection, the Group provides nuclear radiation detection solutions to
the global homeland defence and security market. Kromek's compact, handheld,
high-performance radiation detectors, based on advanced scintillation and
solid-state readout technology, are primarily used to protect critical
infrastructure, events, personnel and urban environments from the threat of
'dirty bombs'.

 

The Group is also developing bio-security solutions in the CBRN detection
segment. These consist of fully automated and autonomous systems to detect a
wide range of airborne pathogens.

 

Kromek is listed on AIM, a market of the London Stock Exchange, under the
trading symbol 'KMK'.

 

Acknowledgement of Sponsorship: This work is supported under the U.S.
Department of Homeland Security, Countering Weapons of Mass Destruction
Office, competitively award contract 70RWMD23C00000025. This support does not
constitute an express or implied endorsement on the part of the Government.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFEWSDMEDSESS